Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 Mos4 HIV tetravalent vaccine - Janssen Vaccines and Prevention B.V

Next Previous
X
Search
Drug Profile

Ad26 Mos4 HIV tetravalent vaccine - Janssen Vaccines and Prevention B.V

Alternative Names: Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos4.HIV; Adenovirus serotype-26 mosaic-4 HIV vaccine; Adenovirus serotype-26 mosaic-4 human immunodeficiency virus vaccine; Tetravalent Ad26 Mos HIV; VAC 89220

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; Janssen Vaccines and Prevention B.V
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV infections
  • Phase I/II Immunodeficiency disorders; Immunological disorders; Retrovirus infections; Sexually transmitted infections

Most Recent Events

  • 02 May 2024 anssen Vaccines & Prevention B.V withdraws prior to enrollment a phase I trial for HIV infections in Thailand (IM, Injection), since protocol was changed during development (NCT05769569)
  • 12 Jan 2024 US Army Medical Research and Development Command and Janssen Vaccines and Prevention plans a phase I trial for HIV infection (Prevention) in January 2024 in Uganda (IM) (NCT06205056)
  • 22 Nov 2023 Janssen Vaccines & Prevention B.V. completes the phase I/II IPCAVD-012 trial in HIV infections (Prevention) in Kenya, Rwanda and the US (NCT02935686)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top